Oral Biologics & Biosimilar Drugs Market Size Forecasted To Achieve $15.11 Billion By 2029 With Steady Growth

The Oral Biologics & Biosimilar Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Oral Biologics & Biosimilar Drugs Market Size and Projected Growth Rate?
The oral biologics & biosimilar drugs market has expanded rapidly in recent years. It will grow from $7.19 billion in 2024 to $8.6 billion in 2025, at a CAGR of 19.6%. This growth is driven by the increasing prevalence of chronic diseases, heightened awareness of oral biologics, patent expirations, and rising demand for biosimilars.

The oral biologics & biosimilar drugs market is forecasted for rapid expansion, growing to $15.11 billion in 2029 at a CAGR of 15.1%, driven by growing interest in targeted treatments, preventative care, rising medical spending, and demographic aging. Trends include improved oral delivery systems, development of orally available biologics, biosimilar innovation, and patient-oriented models.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3792

What Are the Major Segments in the Oral Biologics & Biosimilar Drugs Market?
The oral biologics & biosimilar drugs market covered in this report is segmented -

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others
3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab
2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab
3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp

What Are The Driving Oral Biologics & Biosimilar Drugs Market Evolution?
The oral biologics and biosimilar market is expected to grow due to the rising prevalence of chronic diseases like arthritis, asthma, and cancer. Biologics, which boost the immune system to target diseases like cancer, are becoming more common in the treatment of chronic conditions. The United Nations projects that chronic diseases will account for 70% of global deaths by 2030, driving the demand for biologics and biosimilars.

Which Firms Dominate The Oral Biologics & Biosimilar Drugs Market Segments?
Major companies operating in the oral biologics & biosimilar drugs market include Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., Changchun High & New Technology Industries (Group) Inc., Dong Bao Pharmaceutical Co. Ltd., CP Guojian Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, Concord Biotech Limited, Aurobindo Pharma Limited, H. Lundbeck A/S, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.

What Trends Are Driving Growth in The Oral Biologics & Biosimilar Drugs Market?
A current trend in the oral biologics and biosimilar market is the development of insulin biosimilars. Leading companies in this market are working on creating insulin biosimilars, which is fostering competition among biosimilar producers. For example, in April 2023, Eli Lilly and Company, a US-based manufacturer, launched Rezvoglar (insulin glargine-aglr), a biosimilar for insulin glargine used in managing type 1 and type 2 diabetes.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Which Is The Largest Region In The Oral Biologics & Biosimilar Drugs Market?
The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Oral Biologics & Biosimilar Drugs Market?
2. What is the CAGR expected in the Oral Biologics & Biosimilar Drugs Market?
3. What Are the Key Innovations Transforming the Oral Biologics & Biosimilar Drugs Industry?
4. Which Region Is Leading the Oral Biologics & Biosimilar Drugs Market?

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.